Browse > Article

The Current Status of Adenovirus-based Cancer Gene Therapy  

Shirakawa, Toshiro (International Center for Medical Research and Treatment (ICMRT), Kobe University School of Medicine)
Publication Information
Molecules and Cells / v.25, no.4, 2008 , pp. 462-466 More about this Journal
Abstract
Adenoviruses are the most commonly used gene-delivery vectors due to the efficiency of their in vivo gene transfer. Since 1993, about 300 protocols using an adenoviral vector have been performed, although they have yet to be proven effective in clinical trials. The adenovirus-based vector has been continuously improved by modification of the adenoviral genome and capsid, and novel adenovirus-delivery systems, such as the carrier-cell delivery system, have been recently proposed. Adenovirus-based cancer gene therapy is fast becoming one component of a multi-modality treatment approach to advanced cancer, along with surgery, radiotherapy, and chemotherapy.
Keywords
Adenovirus; Cancer; Gene Therapy;
Citations & Related Records

Times Cited By Web Of Science : 26  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Huebner, R.J., Rowe, W.P., Schatten, W.E., Smith, R.R., and Thomas, L.B. (1956). Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9, 1211-1218   DOI   ScienceOn
2 Lonberg-Holm, K., and Philipson, L. (1969). Early events of virus-cell interaction in an adenovirus system. J. Virol. 4, 323-338
3 Mettler, N.E., Clarke, D.H., and Casals, J. (1982). Virus inoculation in mice bearing Ehrlich ascitic tumors: antigen production and tumor regression. Infect. Immun. 37, 23-27
4 Russell, W.C. (2000). Update on adenovirus and its vectors. J. Gen. Virol. 81, 2573-2604   DOI
5 Vaha-Koskela, M.J., Heikkila, J.E., and Hinkkanen, A.E. (2007). Oncolytic viruses in cancer therapy. Cancer Lett. 254, 178-216   DOI   ScienceOn
6 Vattemi, E., and Claudio, P.P. (2006). Adenoviral gene therapy in head and neck cancer. Drug News Perspect. 19, 329-337   DOI   ScienceOn
7 Hamada, K., Desaki, J., Nakagawa, K., Zhang, T., Shirakawa, T., Gotoh, A., and Tagawa, M. (2007). Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol. Ther. 15, 1121-1128   DOI
8 Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M., and Batshaw, M.L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158   DOI   ScienceOn
9 Shirakawa, T., Terao, S., Hinata, N., Tanaka, K., Takenaka, A., Hara, I., Sugimura, K., Matsuo, M., Hamada, K., Fuji, K., et al. (2007). Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum. Gene Ther. 18, 1225-1232   DOI   ScienceOn
10 Fallaux, F.J., Bout, A., Van der Velde, I., Van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., Van Ormondt, H., Van der EB, A.J., et al. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-com-petent adenoviruses. Hum. Gene Ther. 9, 1909-1917   DOI   ScienceOn
11 Biederer, C., Ries, S., Brandts, C.H., and Mccormick, F. (2002). Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163-175   DOI   ScienceOn
12 Rowe, W.P., Huebner, R.J., Gilmore, L.K., Parrott, R.H., and Ward, T.G. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84, 570-573
13 Freytag, S.O., Stricker, H., Pegg, J., Paielli, D., Pradhan, D.G., Peabody, J., Deperalta-Venturian, M., Xia, X., Brown, S., Lu, M., et al. (2003). Phase I study of replication-competent adenovirus- mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497-7506
14 Power, A.T., and Bell, J.C. (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol. Ther. 15, 660-665   DOI
15 Sakhuja, K., Reddy, P.S., Ganesh, S., Cantaniag, F., Pattison, S., Limbach, P., Kayda, D.B., Kadan, M.J., Kaleko, M., and Connelly, S. (2003). Optimization of the generation and propagation of gutless adenoviral vectors. Hum. Gene Ther. 14, 243-254   DOI   ScienceOn
16 Yu, W., and Fang, H. (2007). Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141-148   DOI   ScienceOn
17 Clayman, G.L., El-naggar, A.K., Lippman, S.M., Henderson, Y.C., Frederick, M., Merritt, J.A., Zumstein, L.A., Timmons, T.M., Liu, T.J., Ginsberg, L., et al. (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232   DOI
18 Southam, C.M., and Moore, A.E. (1952). Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5, 1025-1034   DOI   ScienceOn
19 Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74   DOI   ScienceOn
20 Nemunaitis, J., Swisher, S.G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D.D., Kemp, B.L., et al. (2000). Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18, 609-622   DOI
21 Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G.I., Soutar, D.S., Otto, R., Robertson, A.G., Park, O., Gulley, M.L., Heise, C., et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806
22 Southam, C.M., Hilleman, M.R., and Werner, J.H. (1956). Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man. J. Lab Clin. Med. 47, 573-582
23 Zeimet, A.G., and Marth, C. (2003). Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4, 415-422   DOI   ScienceOn
24 Peng, Z. (2005). Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016-1027   DOI   ScienceOn
25 Mizuguchi, H., and Hayakawa, T. (2004). Targeted adenovirus vectors. Hum. Gene Ther. 15, 1034-1044   DOI   ScienceOn
26 Volpers, C., and Kochanek, S. (2004). Adenoviral vectors for gene transfer and therapy. J. Gene Med. 6 (Suppl. 1), S164-171   DOI   ScienceOn
27 Crystal, R.G., Mcelvaney, N.G., Rosenfeld, M.A., Chu, C.S., Mastrngeli, A., Hay, J.G., Brody, S.L., Jaffe, H.A., Eissa, N.T., and Danel, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51   DOI   ScienceOn
28 Saukkonen, K., and Hemminki, A. (2004). Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther. 4, 683-696   DOI   ScienceOn
29 Kreppel, F., and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 16, 16-29   DOI